Compagnie Lombard Odier SCmA Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Compagnie Lombard Odier SCmA trimmed its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 130,020 shares of the medical device company's stock after selling 4,790 shares during the period. Compagnie Lombard Odier SCmA's holdings in DexCom were worth $8,879,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of DXCM. Norges Bank bought a new position in DexCom in the 4th quarter valued at $385,367,000. Congress Asset Management Co. boosted its holdings in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the period. Fisher Funds Management LTD bought a new position in DexCom in the 4th quarter valued at $96,507,000. Woodline Partners LP bought a new position in DexCom in the 4th quarter valued at $63,338,000. Finally, Northern Trust Corp boosted its holdings in DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the period. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several analyst reports. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Mizuho started coverage on shares of DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. The Goldman Sachs Group started coverage on shares of DexCom in a report on Friday, May 30th. They set a "buy" rating and a $104.00 price objective for the company. Barclays lifted their price objective on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Finally, Robert W. Baird dropped their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.32.

DexCom Trading Down 1.0%

NASDAQ:DXCM traded down $0.86 during trading hours on Friday, reaching $81.99. The company's stock had a trading volume of 2,904,075 shares, compared to its average volume of 4,340,212. The firm has a 50-day simple moving average of $78.50 and a 200-day simple moving average of $79.31. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $117.91. The firm has a market capitalization of $32.15 billion, a price-to-earnings ratio of 57.34, a PEG ratio of 2.30 and a beta of 1.46. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the previous year, the firm posted $0.32 EPS. DexCom's revenue was up 12.5% compared to the same quarter last year. Research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president now owns 109,621 shares in the company, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the sale, the executive vice president now directly owns 95,602 shares in the company, valued at $8,057,336.56. The trade was a 9.47% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,536 shares of company stock worth $1,393,876. 0.32% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.